• The global golf equipment market is estimated at $18.34 billion in 2024 and forecasted to reach $29.3 billion by 2034.
• The company’s recent name change “marks a new chapter in our company’s evolution as we push the boundaries of performance in golf equipment,” says CEO.
• Newton’s advanced physics-driven designs are setting new standards in golf technology, from high-performance shafts to next-generation putters.

The global golf equipment market is experiencing significant growth, driven by increasing participation and technological advancements. This upward trend presents substantial opportunities for companies operating within the golf-equipment sector, such as Newton Golf Company (NASDAQ: NWTG), a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design.

“The global golf equipment market is estimated to be valued at $18.34 billion in 2024 and is forecasted to reach a market size of $29.3 billion by 2034 end, recording a CAGR of 4.8% between 2024 and 2034,” reports Fact.MR (https://ibn.fm/XGn9c). “This business is centered on innovation, technology and performance. Manufacturers are continuously striving to create cutting-edge products that can improve accuracy, distance and overall player performance. Rising participation rates, fueled by the appeal of golf as a leisure activity and networking tool, contribute to increased demand for quality equipment. Globalization and urbanization have led to higher disposable incomes in many regions, enabling more individuals to invest in golf as a recreational activity.”

The report states that key market growth drivers include constant innovation in club design and materials and growing interest in golf, particularly among younger demographics and emerging markets. “The perception of golf as a sport promoting fitness and well-being attracts new enthusiasts, boosting equipment sales,” said the report, while also noting that “endorsements and preferences of professional golfers influence consumer choices, impacting golf equipment market trends.” Fact.MR also pointed out that a general shift toward online shopping has provided greater accessibility to a global consumer base.

This projected growth bodes well for established brands and emerging innovators alike, as they work to capture market share by introducing products that enhance player performance and experience. Amid this thriving industry, Newton Golf Company has emerged as a notable player, dedicated to advancing golf-equipment technology. Formerly known as Sacks Parente, the company rebranded to Newton Golf Company last year and announced an official name change earlier this month (https://ibn.fm/6FMJp).

According to the company, the new name pays tribute to Sir Isaac Newton, whose groundbreaking discoveries in physics forever changed the world’s understanding of motion and force, principles that are fundamental to the game of golf. “Much like Newton’s early insights into gravity and motion shaped modern science, Newton Golf is pioneering a new era in golf performance technology, leveraging cutting-edge engineering to enhance distance, control, and consistency for golfers of all skill levels,” the company stated.

Company chair and CEO Greg Campbell noted that the name change “marks a new chapter in our company’s evolution as we push the boundaries of performance in golf equipment. Isaac Newton’s revolutionary thinking changed the world, and Newton Golf embodies that same spirit of discovery and innovation. Our advanced physics-driven designs are setting new standards in golf technology, from high-performance shafts to next-generation putters.”

Newton Golf focuses on delivering innovative products designed to enhance golfers’ performance, including Newton Motion Shafts and Newton Gravity Putters. The company’s proprietary shafts are engineered to store and release energy more efficiently during swings, resulting in increased distance and accuracy. Its putters are designed with a center of gravity and ultra-low balance point, promoting smooth strokes and a steady tempo.

NWTG is a technology-driven golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company’s expanding portfolio includes innovative golf shafts, putters, grips and other golf-related accessories designed for golfers of all skill levels. With a commitment to superior craftsmanship and performance, Newton Golf continues to push the boundaries of golf technology. 

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, has reiterated its commitment to growing women’s soccer globally
• In a joint report co-authored with leading global law firm Clifford Chance LLP, Brera noted the benefits of its MCO model and the opportunity it presents for the growth of the sport
• Women’s soccer is experiencing unprecedented growth, with record-breaking attendance, extensive media coverage, and increasing investment from celebrities and corporations
• Brera is strategically positioned to capitalize on this momentum, leveraging its MCO model to drive sustainable growth and enhance shareholder value

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, has reiterated its commitment to advancing women’s soccer.

In a joint report co-authored with leading global law firm Clifford Chance LLP, Brera outlines the benefits of MCO models in women’s soccer, the opportunity it presents for the growth of the sport, and for growing both short and long-term shareholder value (https://ibn.fm/BOM9v).

Titled “BREAKAWAY: How Multi-Team Ownership May Reshape Women’s Soccer,” this report offered a behind-the-scenes look MCO models in the sport, specifically detailing its benefits such as financial diversification, operational efficiency, talent acquisition and development, global brand expansion and sponsorship optimization.

For Brera, this model is replicated across all the facets in which it operates, from its men’s soccer teams to its female volleyball teams, a testament to its overall viability and the opportunity it presents from a growth standpoint.

“The rise of multi-club ownership in women’s soccer reflects the increasing sophistication of investment strategies in the sport,” noted Maria Xing, Brera’s Head of Investments and Corporate Development. “As stakeholders seek scalable, sustainable models, MCOs offer a framework for growth, competitive development, and long-term financial stability,” she added (https://ibn.fm/ikKn3).

Brera’s interest and overall focus on women’s teams isn’t new. The company currently operates women’s teams across multiple markets. These include Brera Tchumene in Mozambique, Brera Milano, an amateur club with a social impact focus, and WFC Brera Tiverija, the first for-profit corporation for a North Macedonian football club (https://ibn.fm/BOM9v). Its focus goes beyond soccer, evidenced by its majority stake ownership in UYBA Volley, an Italian women’s professional volleyball team. In addition, the company has expanded its engagement in women’s football in Italy through its 2024/25 season affiliation with Sant’Antonio for the Juve Stabia women’s team.

These investments underscore Brera’s confidence in the future of women’s football and the significant untapped opportunities within the sector. With its growing popularity, women’s soccer is now getting record-breaking attendance, unprecedented media coverage, and celebrity investment and endorsements.

Brera’s teams benefit from a consolidated and geographically diversified balance sheet, access to committed equity financing sources, and favorable debt financing solutions. The MCO model is designed to generate sustainable revenue growth, positioning Brera for higher returns on investment as it expands its portfolio.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• As the social media marketing revenue stream builds toward the trillion-dollar threshold, its access to consumers in the U.S. and around the world creates a powerful tool for advertisers
• Thumzup Media offers an increasingly popular proprietary platform for linking advertisers with social media influencers and their target audiences, democratizing the process in much the same way Uber and Airbnb revolutionized their individual markets
• The company has more than 700 advertiser clients and expects to top 1,000 during the coming summer quarter
• Thumzup’s recent Nasdaq uplisting, as well as its new stock share repurchase program, are both moves seen as advancing shareholder value

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) continues building, helping shareholders after its uplisting to the Nasdaq exchange, announcing recently that board members have approved a stock buyback program of up to $1 million in shares and the company has repurchased $126,507 of its common stock from the open market.

“We believe that this repurchase program reflects our confidence in Thumzup’s growth trajectory and the opportunity to deploy capital strategically,” company CEO Robert Steele stated in the news release dated March 12 (https://ibn.fm/x680k).

Thumzup’s proprietary AdTech platform helps companies simply build and administer their social media advertising campaigns while simultaneously enabling influencers to easily join an open marketing opportunity and receive payment.

“This disruptive platform has the potential to redefine the social media advertising market, much like what Uber accomplished in the transportation space and what Airbnb did to the hospitality market,” Steele wrote in a January letter to shareholders celebrating the company’s achievements during the past year and offering its outlook for 2025 (https://ibn.fm/s5pCR).

Information analysts at Datareportal noted in its Digital 2024: Global Overview Report (https://ibn.fm/6Vw4d) last year indicated that more than 5 billion social media user identities now operate actively online — an increase of more than 200 times during the past 25 years, representing a growing base for companies to target as they market their products to consumers.

Market analysts at Statista predict revenue generated by social commerce will hit the trillion-dollar mark by 2028 (https://ibn.fm/IfIwF).

Thumzup has more than 700 advertising clients and expects that number to top 1,000 this summer. The AdTech model essentially provides a platform for advertisers to buy a marketing campaign at www.thumzupmedia.com, establishing how much the company will pay for social media posts about a brand or business and how many posts it will buy.

A participating influencer with an interest in the target market can then post to friends and acquaintances about that brand or business for the established term. The posts contain a statement that they are part of a paid promotion, the influencer is notified when the promotion has completed its term, and the advertiser can easily renew it if desired, providing the potential for recurring revenue.

Cash payments are made to the influencer via Venmo or PayPal, and Thumzup collects a percentage fee for the campaign. The company is also increasing its Bitcoin holdings and leveraging its digital assets to boost shareholder value.

“Thumzup allows advertisers to pay their customers and fans cash for their posts on social media — something no other company in the market, to our knowledge, currently offers,” Steele stated. “Thumzup is focused on adding small businesses to the platform, as this is a proven strategy to get digital platforms off the ground due to shorter sales cycle and the need for new solutions small business owners face. In the United States, there are more than 33 million small businesses, and an average of 45% buy digital ads in any given year.”

For more information, visit the company’s website at www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

• Adageis is surpassing its Q1 2025 growth targets, reflecting expanding market demand, with investment focused on team expansion, financial infrastructure, and AI development.
• Adageis’ patented AI-driven platform, already covering over 250,000 patient lives, optimizes quality healthcare for patients and revenue for healthcare providers.
• The company projects 580,000 patient lives covered by the end of Q2 2025.

Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is set to exceed its Q1 2025 growth expectations as its AI-powered platform continues to gain traction in the healthcare sector. The company now covers more than 250,000 patient lives, a sharp increase from its previously reported 150,000. This growth highlights a rising demand for technology that helps providers successfully transition from fee-for-service models to value-based care.

The company’s expansion is being driven by its ProActive Care Platform, an AI-powered system designed to streamline operations and improve revenue performance for healthcare providers. Currently utilized by 70 providers, the platform integrates with more than 90 electronic health record (“HER”) systems and has been awarded a U.S. patent for its predictive analytics capabilities.

Adageis plans to allocate its recent growth funding, as well as raised capital, toward three key areas: expanding its team to support the existing platform, upgrading financial infrastructure to launch into healthcare factoring, and enhancing its AI technology. The company expects to cover 580,000 patient lives by the end of Q2 2025, with monthly recurring revenue projected to reach $100,000. Additionally, Adageis is onboarding two to three new clients per month, further solidifying its unique position in the market.

Adageis is positioning itself as a key player in healthcare fintech, offering solutions that help providers optimize cash flow and maximize reimbursements. The company’s Patented Risk Engine (“PRE”) utilizes predictive analytics to assess revenue performance, enabling providers to forecast quality incentive payments. This capability allows healthcare organizations to factor accounts receivables and leverage debt for operational expansion.

The fintech AI solution is designed to address the complexities of insurance contracts, aggregating payments from insurance companies, accountable care organizations (“ACOs”), independent physician associations (“IPAs”), and clinically integrated networks (“CINs”). By providing these insights, Adageis enables healthcare professionals to secure funding based on expected reimbursements, reducing financial uncertainty.

A key factor in Adageis’ success is its ability to integrate seamlessly with widely used healthcare platforms, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic. This interoperability ensures that providers can implement the ProActive Care Platform without overhauling their existing systems, making it an attractive option for healthcare organizations looking to transition to value-based care.

The healthcare sector’s shift toward value-based care has created a demand for technology that can optimize revenue while improving patient outcomes. Adageis’ AI-powered platform is currently the only offering of its kind, providing an automated, scalable solution for healthcare providers navigating this transition.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Clene’s CNM-Au8^® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months.
• The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control.
• Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial.
• The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has released new data showing that its lead drug candidate, CNM-Au8, significantly extends survival in patients with ALS. The findings were derived from a cross-regimen post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants (https://ibn.fm/EgWeb).

The study compared participants treated with CNM-Au8 30 mg (Regimen C) against those in Regimen A, which served as a large concurrent control group. Survival data was tracked over 48 months using public records and site reporting. The majority (78%) of patients in both groups received standard ALS treatments such as riluzole and edaravone, or both.

Key findings of the analysis include:

• Patients in the CNM-Au8 30 mg group of Regimen C had a median survival of 951 days, compared to 753 days in the control group — a 6.5-month improvement. When adjusted for key variables such as baseline disease severity and biomarker levels, the restricted mean survival time (“RMST”) analysis showed a statistically significant 4.1-month increase in survival (p=0.045).
• In patients with moderate to severe ALS, the median survival improvement was greater, rising from 589 days (Regimen A) to 951 days (a gain of 11.9 months). In this subgroup, the mortality risk was reduced by 44%, with an RMST improvement of 197 days.
• The largest benefit was seen in patients meeting the criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. This group experienced a median survival of 1079 days, 14.8 months longer than the control group (628 days), a 49% reduction in mortality risk, and an RMST improvement of 215 days.

These results align with prior studies, including the 24-week HEALEY ALS Platform Trial double-blind period, the RESCUE-ALS trial, and Expanded Access Program data. Commenting on the findings, Merit Cudkowicz, M.D., M.Sc., Principal Investigator and sponsor of the HEALEY ALS Platform Trial, director of the Sean M. Healey & AMG Center for ALS, and executive director of the Mass General Brigham Neuroscience Institute, said, “The innovative design of the HEALEY ALS Platform Trial has enabled us to extract clear and meaningful survival data that helps make decisions about CNM-Au8 drug development.”

Clene is seeking to bring CNM-Au8 to market as soon as possible. The company is preparing to launch a confirmatory Phase 3 RESTORE-ALS trial in mid-2025, while also considering an accelerated approval pathway for CNM-Au8, following discussions with the FDA in late 2024. As part of this process, Clene will conduct additional biomarker analyses, focusing on neurofilament light chain (“NfL”) data—an important measure of ALS progression.

Rob Etherington, Clene’s President and CEO, expressed optimism about the results, stating that the survival benefit reinforces CNM-Au8’s potential to extend life for people living with ALS while also validating the company’s strategic direction as it prepares for the launch of the confirmatory Phase 3 RESTORE-ALS study in mid-2025. “We look forward to discussing these findings with the FDA as we advance toward potential commercialization,” he said.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• D-Wave has shown quantum computational supremacy on a useful, real-world problem, a first in the industry, highlighting the potential of quantum computing for materials discovery and complex simulations beyond classical computational limits.
• A peer-reviewed paper published in Science validates that D-Wave’s annealing quantum computer solved a magnetic materials simulation problem that is beyond the capabilities of classical supercomputers.
• The simulation, which took minutes to solve on D-Wave’s system, would require nearly one million years and more electricity than the world’s annual consumption on a GPU-based supercomputer.
• The Advantage2 annealing quantum computer prototype was used to achieve this milestone and is available for commercial use.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has confirmed a major milestone in quantum computing, demonstrating quantum computational supremacy on a practical, real-world problem. A newly published, peer-reviewed paper in Science validates that D-Wave’s annealing quantum computer outperformed a state-of-the-art classical supercomputer in simulating quantum dynamics in magnetic materials. The full study, titled “Beyond-Classical Computation in Quantum Simulation,” is available at https://ibn.fm/VEsx9.

This marks the first time quantum computing has been proven to surpass classical methods on a useful, real-world problem (https://ibn.fm/H94kF). Unlike previous claims that focused on abstract mathematical problems or random number generation, D-Wave’s work addresses computational challenges in materials science, a field with implications for medical imaging, superconductors, and electronics.

An international collaboration of scientists led by D-Wave used the company’s Advantage2 annealing quantum computer prototype to simulate quantum dynamics in programmable spin glasses—complex magnetic materials that are difficult to model using conventional methods. D-Wave compared the performance against the Frontier supercomputer at Oak Ridge National Laboratory, one of the most powerful classical supercomputers available.

The results were impressive — D-Wave’s system completed the most complex simulations in minutes. Performing the same computations on the classical supercomputer would have taken nearly one million years and consumed more electricity than the world’s total annual energy consumption.

According to Dr. Alan Baratz, CEO of D-Wave, this achievement underscores the capabilities of quantum annealing. “This is a remarkable day for quantum computing. Our demonstration of quantum computational supremacy on a useful problem is an industry first. All other claims of quantum systems outperforming classical computers have been disputed or involved random number generation of no practical value,” said Dr. Baratz. “Our achievement shows, without question, that D-Wave’s annealing quantum computers are now capable of solving useful problems beyond the reach of the world’s most powerful supercomputers. We are thrilled that D-Wave customers can use this technology today to realize tangible value from annealing quantum computers.”

The ability to accurately simulate quantum materials has broad implications. Magnetic materials play a crucial role in numerous industries, from healthcare to renewable energy. Understanding their behavior through quantum simulations could lead to breakthroughs in designing more efficient electronic components, optimizing medical imaging technologies, and improving energy storage solutions.

According to Dr. Andrew King, senior distinguished scientist at D-Wave, this research proves that D-Wave’s quantum computers can reliably solve complex materials simulation problems that could lead to discovery of new materials. “Through D-Wave’s technology, we can create and manipulate programmable quantum matter in ways that were impossible even a few years ago.”

“This is a significant milestone made possible through over 25 years of research and hardware development at D-Wave, two years of collaboration across 11 institutions worldwide, and more than 100,000 GPU and CPU hours of simulation on one of the world’s fastest supercomputers as well as computing clusters in collaborating institutions,” said Dr. Mohammad Amin, chief scientist at D-Wave. “Besides realizing Richard Feynman’s vision of simulating nature on a quantum computer, this research could open new frontiers for scientific discovery and quantum application development.”

The Advantage2 System

The study builds on earlier research published in Nature Physics (2022) and Nature (2023), which demonstrated that quantum annealing provides a computational speedup for optimization problems. These findings led to the development of Advantage2’s fast anneal feature, which played a crucial role in this latest breakthrough. D-Wave also continues to develop and advance its quantum hardware, with a current Advantage2 prototype quantum computer that is four times larger than the prototype used in this study.

D-Wave offers customers immediate access to the Advantage2 prototype quantum computer through D-Wave’s Leap™ quantum cloud service, allowing businesses and researchers to explore its capabilities today. The prototype provides substantial performance improvements from previous-generation Advantage^TM systems, including increased qubit coherence, connectivity, and energy scale, which enables higher-quality solutions to larger, more complex problems.

Industry Response

The results of the study have drawn interest from the broader scientific community. Dr. Seth Lloyd, Professor of Quantum Mechanical Engineering at MIT, commented: “Although large-scale, fully error-corrected quantum computers are years in the future, quantum annealers can probe the features of quantum systems today. In an elegant paper, the D-Wave group has used a large-scale quantum annealer to uncover patterns of entanglement in a complex quantum system that lie far beyond the reach of the most powerful classical computer.”

Other leading physicists, including Dr. Hidetoshi Nishimori (Tokyo Institute of Technology) and Dr. Juan Carrasquilla (ETH Zürich), have echoed similar sentiments, recognizing the significance of this breakthrough in advancing quantum computing research.

“This paper is not only a tour-de-force for experimental physics, it is also remarkable for the clarity of the results. The authors have addressed a problem that is regarded both as important and as very challenging to a classical computer,” said Dr. Victor Martin-Mayor, Professor of Theoretical Physics, Universidad Complutense de Madrid. “The team has shown that their quantum annealer performs better at this task than the state-of-the-art methods for classical simulation.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports s, has announced the appointment of Dr. Arthur B. Laffer to its Advisory Board.
• With an economic lens, Dr. Laffer can provide strategic guidance on securing high-value sponsorship agreements, optimizing broadcasting rights negotiations, and leveraging government incentives to support Brera’s global expansion. Additionally, Dr. Laffer may help refine Brera’s financial modeling for player salary structures, transfer market efficiency, and overall profitability.
• Dr. Laffer’s appointment points to Brera’s ambitions for the 2025 calendar year and follows the company’s recent investment in a Mozambican football club, along with 10 new signings in the 2024-2025 winter transfer window.

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, has announced the addition of Dr. Arthur B. Laffer to its Advisory Board. His strategic input to the company can help develop Brera’s proprietary financial models to optimize player salaries, transfer fees, and overall profitability. In addition, his corporate and political networks could be integral in positioning Brera’s clubs as transatlantic brands, providing exposure to American investors (https://ibn.fm/J5alM).

“Dr. Laffer’s economic expertise and strategic insights into market expansion and asset monetization make him a powerful addition to our all-star Advisory Board,” noted Daniel McClory, Brera’s Executive Chairman. “His principles, including the Laffer Curve, offer a unique perspective on optimizing revenue while maintaining operational efficiency,” he added (https://ibn.fm/J5alM).

Dr. Laffer is recognized for creating and popularizing the Laffer Curve, which depicts the relationship between tax rates and revenue. Created back in 1974, this curve offers a visual representation of total tax revenue collected by governments as varying depending on tax rates. As such, it is often used to illustrate the argument that tax cuts can, if properly calculated, increase total tax revenue. Globally, this curve has influenced fiscal policy, and Brera believes that, with Dr. Laffer’s extensive experience advising U.S. policymakers, corporate leaders, and investors, he will bring a fresh economic dimension to Brera’s football expansion strategy. His advisory role is intended to focus on optimizing revenue streams, monetizing player assets, and ensuring sustainable club profitability (https://ibn.fm/J5alM).

Dr. Laffer will join Massimo Ferragamo, Alan Rothenberg, Giuseppe Rossi, Paul Tosetti, and Marshall Geller on Brera’s all-star Advisory Board, with his connections in finance, energy, and technology expected to be instrumental in accessing relationships for potential high-value sponsorship deals, broadcasting rights and government incentives. For Brera, his addition will help shape the company’s vision of maximizing player monetization, revenue streams, and international market penetration, particularly in and from Asia and North America.

“We were diligent in ensuring that Brera’s Advisory Board provides visionary leadership as we continue to drive our MCO strategy forward,” noted Mr. McClory (https://ibn.fm/J5alM).

Dr. Laffer’s appointment reflects Brera’s long-term vision of positioning football clubs as high-value global assets. This follows the company’s recent expansion efforts, including a signed letter of intent (“LOI”) to invest in a second Mozambican football club and securing 10 new player signings in the 2024-2025 winter transfer window.

For company information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• Thumzup Media deploys a proprietary social media marketing platform branded AdTech that drives influencers to slingshot the effectiveness of small-business advertising
• The company is maintaining growth of more than 200% CAGR, currently representing more than 700 advertiser clients, with expectations of surpassing 1,000 during the coming financial reporting quarter
• Thumzup has now uplisted to the Nasdaq stock index drawing more attention to its growing success in the social media marketing sector, a more-than-$500 billion digital revenue stream expected to pass the trillion-dollar mark by 2028

Social media marketing has grown exponentially since the turn of the century, when some 25 million social media identities existed worldwide. Last year’s Digital 2024: Global Overview Report by DataReportal (https://ibn.fm/zfypb) found that there were now well over 5 billion active social media user identities — an increase of more than 200 times during the past 25 years, with marketing tools adapting to the growth during that time.

The report found that nearly 53% of internet users said the primary reason they use social media is to find products to purchase or inspiration for purchases. And the trend only continues to grow — market analysts at Statista predict revenue generated by social commerce will hit the trillion-dollar mark by 2028 (https://ibn.fm/iatWr).

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) recently uplisted to the NASDAQ, further building its momentum as a solution to industry growth challenges through its proprietary AdTech platform, which significantly enhances the influencer recruiting and payment process. The company now represents more than 700 advertisers and expects to pass the 1,000-advertiser threshold during this year’s Q2 period.

As social media marketing growth attempts to accelerate, it is growing more sophisticated. More brands are competing online for consumers’ attention, and consumers are evolving in terms of their behaviors and preferences (https://ibn.fm/l6Sv3). Thumzup Media’s easy-to-use dashboard allows advertisers to programmatically customize their campaign, using a consumer-facing app to facilitate cash payment to social media users based on their posting success on advertisers’ behalf.

Thumzup also recently announced plans to integrate bitcoin as an additional payment option for gig economy workers.

“Our rapid growth to more than 700 advertisers, up from around 200 this time last year, is confirmation of the effectiveness of our disruptive advertising model,” Thumzup CEO Robert Steele stated in a company news release earlier this month (https://ibn.fm/V2YZW). “We are maintaining growth of more than 200% CAGR. … We are continuously growing and redefining how brands connect with consumers. By incentivizing engagement with direct cash rewards and harnessing a vast, untapped audience, we are delivering outsized value.”

For more information, visit the company’s website at www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

Adageis is opening a Series A funding round, capital raise, aiming to raise $10 million for growth and expansion.
The company previously closed a $2 million seed round in Q4 2024 to enhance operations and market reach.
Adageis expects to exceed growth targets for Q1 2025, with strong market adoption of its AI-powered platform designed to streamline healthcare operations, optimize revenue, and improve patient care outcomes.
The company has cut onboarding time from four weeks to one week, accelerating customer acquisition and revenue growth.

Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is launching a Series A funding round to raise $10 million in growth capital. This follows the company’s successful $2 million seed round at the end of Q4 2024, which supported backend improvements, expanded electronic health record (“EHR”) connectivity, and an increased sales force.

The company is targeting a total of $20 million in funding to fuel its next phase of growth, with a minimum investment of $250,000 required to participate. The capital will be allocated as follows:

40%: Expansion of SaaS platform team
45%: Development of a healthcare factoring division
15%: Technology upgrades to support fintech AI transition

Adageis is positioning itself as a key player in healthcare financial technology, helping providers optimize revenue and streamline operations. Representing the only offering of its kind in the healthcare sector, the company’s AI-powered ProActive Care Platform enables providers a more effective way to transition from traditional fee-for-service models to value-based care, improving both patient outcomes and financial performance.

The company’s Patented Risk Engine (“PRE”) enables predictive analytics for revenue performance, identifying patterns in patient care and financial incentives. Key financial benefits include:

Cash Flow Management: AI can predict revenue performance from quality incentives, enabling providers to factor accounts receivables for pay-per-performance payments.
Debt Leverage: Healthcare professionals can use AI-driven insights to access funding for operations and expansion, aggregating payments from insurance companies, ACOs, IPAs, and CINs.

Adageis’ fintech AI solutions are designed to simplify the complexities of insurance contracts, making it easier for providers to maximize reimbursements. By seamlessly integrating with widely used platforms like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization.

The company expects to exceed its Q1 2025 growth targets, highlighting market demand for its services. Up to date, the company reports 150,000 patient lives currently covered, 70 providers across two states using the platform, one awarded patent from the USPTO, integration with over 90 EHR systems and up to $75,000 per provider in additional value-based care revenue.

By the end of Q2 2025, Adageis anticipates:

580,000 patient lives covered
$100,000 in monthly recurring revenue
Two to three new clients onboarded per month

To support this expansion, the company has streamlined its onboarding process, reducing implementation time from four weeks to just one week.

With its upcoming Series A funding round, Adageis is positioning itself for significant expansion in the healthcare technology space, offering investors an opportunity to support a rapidly growing company in the evolving $19.27 billion healthcare AI market.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals.
• The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications.
• Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives.
• The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease.
• Soligenix is led by an experienced management team with a strong track record of success.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (“SGX301”), a novel photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”). Additional candidates in development target psoriasis (“SGX302”), oral mucositis (“SGX942”), and Behçet’s disease (“SGX945”), while its public health efforts focus on heat-stable vaccines for ricin poisoning (“RiVax®”), Ebola (“SuVax™”), and Marburg (“MarVax™”) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.

SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (“PRVs”) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at http://ibn.fm/SNGX